Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2024 08:20 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.
January 29, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
January 22, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

Arcutis today announced the launch of ZORYVE® (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis
September 25, 2023 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.
February 21, 2023 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...
September 06, 2022 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
June 06, 2022 07:30 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle...
July 12, 2021 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis

Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million patients in the U.S.Potential first new topical treatment for seborrheic dermatitis in...